2024
Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor
Brösecke F, Pfau A, Ermer T, Dein Terra Mota Ribeiro A, Rubenbauer L, Rao V, Burlein S, Genser B, Reichel M, Aronson P, Coca S, Knauf F. Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor. Scientific Reports 2024, 14: 11323. PMID: 38760468, PMCID: PMC11101424, DOI: 10.1038/s41598-024-61808-7.Peer-Reviewed Original ResearchConceptsIL-16 levelsIL-16Dialysis patientsCardiovascular eventsConcentrations of IL-16Kidney failureUremic toxinsCardiovascular diseaseCompared to healthy individualsPlasma oxalate concentrationActivated immune cellsAssociated with cardiovascular diseaseIL-16 concentrationCytokine IL-16Cardiovascular risk factorsNo significant associationPlasma oxalateInflammatory markersImmune cellsCytokine concentrationsInterleukin-16US patientsCohort 1Cardiovascular outcomesHealthy individualsOxalate Metabolism: From Kidney Stones to Cardiovascular Disease
Hawkins-van der Cingel G, Walsh S, Eckardt K, Knauf F. Oxalate Metabolism: From Kidney Stones to Cardiovascular Disease. Mayo Clinic Proceedings 2024, 99: 1149-1161. PMID: 38762815, DOI: 10.1016/j.mayocp.2024.02.006.Peer-Reviewed Original Research
2020
Assessment of Plasma Oxalate Concentration in Patients With CKD
Pfau A, Wytopil M, Chauhan K, Reichel M, Coca SG, Aronson PS, Eckardt KU, Knauf F. Assessment of Plasma Oxalate Concentration in Patients With CKD. Kidney International Reports 2020, 5: 2013-2020. PMID: 33163722, PMCID: PMC7609998, DOI: 10.1016/j.ekir.2020.08.029.Peer-Reviewed Original ResearchChronic kidney diseasePlasma oxalate concentrationGerman Chronic Kidney Disease (GCKD) studyChronic Kidney Disease studyObservational cohort studyGlomerular filtration rateLarge patient cohortKidney Disease studyKidney stone diseaseCKD progressionMedian eGFROngoing multicenterCohort studyKidney diseasePatient cohortPresent studyFiltration rateClinical trialsStone diseaseLarge cohortOxalate homeostasisPatientsDisease StudyPlasma samplesMaintenance of samples
2017
Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease
Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F. Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease. Kidney International Reports 2017, 2: 1050-1058. PMID: 29270514, PMCID: PMC5733827, DOI: 10.1016/j.ekir.2017.06.002.Peer-Reviewed Original ResearchEnd-stage renal diseasePlasma oxalate concentrationRenal diseaseCalcium oxalate supersaturationPlasma of patientsTraditional therapeutic regimensExtended treatment timeTherapeutic regimensExtended hemodialysisUremic toxin removalHemodialysisTherapeutic strategiesTreatment sessionsPatientsBaseline pDialysis equipmentHemodialfiltrationWeeksTreatment timeOxalate concentrationRespective treatmentsDiseasePrevious reportsTreatment modeHours